Literature DB >> 758396

High-dose propranolol therapy in the management of supraventricular tachycardia.

A S Pickoff, L Zies, P L Ferrer, D Tamer, G Wolff, O Garcia, H Gelband.   

Abstract

Five patients, age 3 weeks to 11 years, presented with supraventricular tachycardia that remained uncontrolled following adequate digitalization. Four of these patients underwent invasive electrophysiologic studies to determine the mechanism of the arrhythmias. Of these four patients, three had concealed Wolff-Parkinson-White syndrome, and one patient had evidence of dual A-V nodal pathways. Propranolol was added to the medical treatment and was administered orally in doses ranging from 7 to 14 mg/kg/day (average 9 mg/kg/day). All five children remain free of their tachycardia except for one patient who occasionally has supraventricular tachycardia with febrile illnesses. No adverse reactions to these high doses of propranolol were encountered.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 758396     DOI: 10.1016/s0022-3476(79)80381-9

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  5 in total

1.  Cardiac diagnostics before oral propranolol therapy in infantile hemangioma: retrospective evaluation of 234 infants.

Authors:  Giovanni Frongia; Ji-Oun Byeon; Raoul Arnold; Arianeb Mehrabi; Patrick Günther
Journal:  World J Pediatr       Date:  2018-05-23       Impact factor: 2.764

2.  Propranolol induced bradycardia in tetralogy of Fallot.

Authors:  D J Clark; K C Chan; J L Gibbs
Journal:  Br Heart J       Date:  1989-04

3.  Long-term efficacy and safety of atenolol for supraventricular tachycardia in children.

Authors:  A V Mehta; A B Subrahmanyam; R Anand
Journal:  Pediatr Cardiol       Date:  1996 Jul-Aug       Impact factor: 1.655

4.  The medical management of pediatric arrhythmias.

Authors:  Carolina Escudero; Roxane Carr; Shubhayan Sanatani
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-10

5.  Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma.

Authors:  Jennifer K Wolter; Nikolaus E Wolter; Alvaro Blanch; Teresa Partridge; Lynn Cheng; Daniel A Morgenstern; Monika Podkowa; David R Kaplan; Meredith S Irwin
Journal:  Oncotarget       Date:  2014-01-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.